Addendum to: “Dapoxetine for the Treatment of Premature Ejaculation: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial in 22 Countries” [Eur Urol 2009;55:957–68]

Clinical outcome registries and real-world evidence databases could validate novel treatment protocols, supporting regulatory approvals and insurance coverage expansion. Biosimilar development for biologically-derived PE therapeutics represents emerging opportunity as multiple biologics enter development pipelines. Integration of behavioral health platforms with pharmaceutical management through digital therapeutics could expand therapeutic efficacy and improve patient outcomes across treatment modalities. Key market threats include pricing pressure from generic dapoxetine formulations and off-label SSRI prescriptions, with generic market share expanding from 28% in 2020 to 54% by 2025, compressing pharmaceutical manufacturer margins from 68% to 72% historically to 34% to 42% currently. Regulatory restrictions on online pharmacy operations in certain markets including the European Union could disrupt the fastest-growing distribution channel, potentially reducing overall market growth by 1.8% to 2.4%. Treatment failure rates of 18% to 24% among certain PE phenotypes, particularly comorbid cases, limit market expansion potential and create patient frustration driving abandonment of treatment-seeking. Psychological and lifestyle counseling alone demonstrate comparable efficacy to pharmaceutical interventions in certain patient subsets, creating competition from lower-cost behavioral alternatives; behavioral therapy reimbursement expansion could cannibalize pharmaceutical segment revenues by 12% to 18% through 2033.

• Some Spanish clinics offer dapoxetine as part of erectile dysfunction therapy.
• Dapoxetine is sometimes combined with other PE management techniques.
• The drug's approval in Spain was based on multiple clinical trials.
• Dapoxetine is dispensed with a proper medical prescription.
• Use of dapoxetine is sometimes supported by lifestyle changes.
• It is crucial to adhere to prescribed dosages for safety.
• Dapoxetine offers quick relief for men suffering from PE.

Data privacy concerns regarding digital health platforms handling sensitive sexual health information could limit telehealth market expansion in privacy-conscious jurisdictions including Europe and parts of Asia. Stigma persistence in traditionally conservative cultures continues limiting treatment-seeking, with PE treatment adoption remaining below 5% of affected populations in certain Middle Eastern and East Asian markets despite clinical need. COVID-19 pandemic normalization and return to in-person healthcare could reduce telehealth utilization from 34% back to estimated 18% to 22%, limiting digital-driven market expansion. The competitive landscape for premature ejaculation treatment is characterized by fragmented markets with distinct competitive dynamics across pharmaceutical, behavioral, and device segments. The pharmaceutical segment remains dominated by major multinational pharmaceutical corporations benefiting from established manufacturing capabilities, regulatory relationships, and distribution networks. Takeda Pharmaceutical maintains market leadership through dapoxetine formulations, generating $127 million in revenues during 2025 through controlled direct marketing and partnerships with telehealth platforms. Pfizer Inc., leveraging its extensive urology portfolio including sildenafil and tadalafil, has integrated dapoxetine licensing into comprehensive sexual dysfunction platforms, capturing 18% of the pharmaceutical PE treatment market segment. Eli Lilly and Company has expanded sexual dysfunction treatment capabilities through tadalafil-based approaches and emerging novel compounds, positioning for competitive growth through the forecast period.

Use In Driving And Operating Machinery

Traditional private practice sex therapists and licensed marriage and family therapists operate as local competitors with limited geographic reach, though professional associations including the American Association of Sexuality Educators, Counselors and Therapists (AASECT) provide quality standards and patient referral mechanisms. Digital therapy platforms including BetterHelp, Talkspace, and Psychology Today's therapist marketplace have introduced scalable behavioral PE treatment options, competing directly against traditional individual therapy practices through convenience and potentially lower costs. Large telehealth platforms including Teladoc and Amwell have incorporated behavioral health specialists as differentiating offerings within comprehensive sexual health programs. Hospital and clinic-based sexual medicine departments compete through integrated sildenafil and dapoxetine behavioral and pharmaceutical management, leveraging specialist expertise as competitive advantage. Academic institutions including Mayo Clinic, Johns Hopkins University, and University of California San Francisco maintain competitive advantage through clinical research leadership and specialized training programs, attracting high-complexity patients willing to travel for expert consultation.

Neurocognitive safety

The device segment competitive landscape remains highly fragmented with numerous small manufacturers and niche players. Established topical anesthetic brands including Stud 100 and Promescent maintain market presence through decades of brand recognition, though facing competition from emerging private label topical products sold through online retailers. Major sexual wellness companies including LELO, We-Vibe, and Adam & Eve have expanded from reproductive pleasure devices into PE-directed therapeutic options, leveraging existing distribution channels and brand awareness. Medical device manufacturers including Boston Scientific and Abbott have initiated exploration of PE treatment devices through partnership and acquisition opportunities, bringing substantial manufacturing and regulatory expertise. Emerging digital and wearable device manufacturers remain largely venture-backed startups with limited market penetration but substantial innovation pipelines; companies including Kiiroo and Skyn have developed interconnected devices with biofeedback capabilities targeting PE populations. Bayer AG, GlaxoSmithKline, and Merck & Co. maintain presence through SSRI formulations and licensed generic agreements, collectively controlling approximately 24% of the pharmaceutical PE treatment market.

Generic manufacturers including Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Viatris have expanded market presence through low-cost dapoxetine and SSRI generic formulations, capturing 34% market share and substantially compressing branded manufacturer pricing power. Emerging pharmaceutical competitors from India and China, including companies like Cadila Healthcare and China Biologic Products, have entered PE treatment markets through generic offerings and novel formulations, intensifying competitive pressure.

Negative Effects Of Usage

Competition within behavioral therapy markets remains fragmented among independent sex therapists, psychological practices, and emerging digital therapy platforms. Traditional private practice sex therapists and licensed marriage and family therapists operate as local competitors with limited geographic reach, though professional associations including the American Association of Sexuality Educators, Counselors and Therapists (AASECT) provide quality standards and patient referral mechanisms.

• In Spain, dapoxetine is prescribed after medical evaluation.
• Common side effects include nausea, dizziness, and headache.
• Dapoxetine's availability varies between pharmacies across Spain.
• It is often part of treatment for men with lifelong premature ejaculation.
• Dapoxetine can be used alone or with behavioral therapy.
• The drug is usually taken on an as-needed basis.
• Price of dapoxetine in Spain varies depending on the pharmacy.

Digital therapy platforms including BetterHelp, Talkspace, and Psychology Today's therapist marketplace have introduced scalable behavioral PE treatment options, competing directly against traditional individual therapy practices through convenience and potentially lower costs. Large telehealth platforms including Teladoc and Amwell have incorporated behavioral health specialists as differentiating offerings within comprehensive sexual health programs. Hospital and clinic-based sexual medicine departments compete through integrated sildenafil and dapoxetine behavioral and pharmaceutical management, leveraging specialist expertise as competitive advantage. Academic institutions including Mayo Clinic, Johns Hopkins University, and University of California San Francisco maintain competitive advantage through clinical research leadership and specialized training programs, attracting high-complexity patients willing to travel for expert consultation. The device segment competitive landscape remains highly fragmented with numerous small manufacturers and niche players. Established topical anesthetic brands including Stud 100 and Promescent maintain market presence through decades of brand recognition, though facing competition from emerging private label topical products sold through online retailers. Major sexual wellness companies including LELO, We-Vibe, and Adam & Eve have expanded from reproductive pleasure devices into PE-directed therapeutic options, leveraging existing distribution channels and brand awareness.

Medical device manufacturers including Boston Scientific and Abbott have initiated exploration of PE treatment devices through partnership and acquisition opportunities, bringing substantial manufacturing and regulatory expertise. Emerging digital and wearable device manufacturers remain largely venture-backed startups with limited market penetration but substantial innovation pipelines; companies including Kiiroo and Skyn have developed interconnected devices with biofeedback capabilities targeting PE populations. Regulatory pathways for device classification remain evolving; most PE-related devices operate in the unregulated or minimally-regulated supplement category, creating opportunities for rapid market entry but limiting clinical validation potential. Top competitors in the global premature ejaculation treatment market during 2025 included Takeda Pharmaceutical commanding $127 million in dapoxetine-specific revenues, Pfizer leveraging integrated sexual dysfunction portfolios generating estimated $284 million in PE-related revenues, Eli Lilly with $89 million in PE treatment-related business, and Bayer AG with $76 million through integrated sildenafil-tadalafil combinations.

• Public awareness about PE has increased, reducing stigma and encouraging seeking help.
• Reliable information in Spanish is available from the AEMPS or medical society websites.
• Patient support groups or forums can provide shared experiences but not medical advice.
• A positive and patient attitude from both partners aids the treatment process.
• Treatment aims to improve sexual satisfaction and overall quality of life.
• Success is not solely about duration but about increased control and reduced anxiety.
• Openly discussing treatment expectations with your doctor is important.
• Sexual health is an integral part of overall well-being.
• Taking the step to consult a doctor is the most important action.

Generic manufacturers Sun Pharmaceutical, Teva, and Viatris collectively generated approximately $410 million through low-cost generic formulations. Emerging digital health competitors including Ro, Hims, and Roman collectively generated estimated $340 million in PE treatment revenues through subscription platforms and direct-to-consumer models during 2025.

Buy Dapoxetine Tablets

Behavioral health platforms including BetterHelp and Talkspace captured approximately $210 million in PE treatment-related revenues through licensed therapist networks.

Study record dates

Regulatory pathways for device classification remain evolving; most PE-related devices operate in the unregulated or minimally-regulated supplement category, creating opportunities for rapid market entry but limiting clinical validation potential. Top competitors in the global premature ejaculation treatment market during 2025 included Takeda Pharmaceutical commanding $127 million in dapoxetine-specific revenues, Pfizer leveraging integrated sexual dysfunction portfolios generating estimated $284 million in PE-related revenues, Eli Lilly with $89 million in PE treatment-related business, and Bayer AG with $76 million through integrated sildenafil-tadalafil combinations. Generic manufacturers Sun Pharmaceutical, Teva, and Viatris collectively generated approximately $410 million through low-cost generic formulations. Emerging digital health competitors including Ro, Hims, and Roman collectively generated estimated $340 million in PE treatment revenues through subscription platforms and direct-to-consumer models during 2025. Behavioral health platforms including BetterHelp and Talkspace captured approximately $210 million in PE treatment-related revenues through licensed therapist networks.

Chemical Names

Device manufacturers including Stud 100 parent company maintained market presence with $78 million in annual PE-related device revenues, while emerging device companies remained largely pre-commercial or early-stage revenue generation. Branded dapoxetine commanded premium pricing of $1.80 to $2.40 USD per dose through 2025, while generic equivalents were priced at $0.48 to $0.72 USD, representing 70% to 78% cost reduction and driving generic market capture from 28% in 2020 to 54% by 2025. Branded formulations maintain competitive positioning through superior marketing, established physician relationships, and patient preference driven by perceived superior quality, though clinical efficacy remains equivalent between branded and generic dapoxetine formulations across randomized trials. Market Share 2025: 58.4%Valuation: $2.45 billionCAGR (2025-2033): 9.1%Includes: Dapoxetine, SSRIs, topical anesthetics, combination therapiesKey Driver: FDA approvals, insurance coverage expansion, telehealth accessibility Market Share 2025: 23.8%Valuation: $998 millionCAGR (2025-2033): 10.4%Includes: Cognitive-behavioral therapy, sex therapy, couples counseling, start-stop techniqueKey Driver: Patient preference, improved therapist training, insurance coverage expansion Market Share 2025: 17.8%Valuation: $746 millionCAGR (2025-2033): 11.4%Includes: Topical anesthetic devices, mechanical solutions, vibration therapy, wearablesKey Driver: Innovation, non-systemic safety profiles, technological advancement Market Share 2025: 29.4%Valuation: $1.23 billionCAGR (2025-2033): 8.2%Services: Specialty sexual medicine departments, multidisciplinary teams, complex case managementOpportunity: Telemedicine expansion, integrated care coordination Market Share 2025: 34.2%Valuation: $1.44 billionCAGR (2025-2033): 10.6%Services: Specialized sexual medicine, urology practices, dermatology integrationOpportunity: Network expansion, emerging market penetration Market Share 2025: 19.8%Valuation: $832 millionCAGR (2025-2033): 15.2%Services: Digital consultations, direct fulfillment, subscription models, convenience accessOpportunity: Regulatory expansion, payment innovation Market Share 2025: 16.6%Valuation: $696 millionCAGR (2025-2033): 4.1%Services: Traditional brick-and-mortar operations, counseling, in-person consultationsOpportunity: Hybrid clinic models, underserved populations Market Share 2025: 67.2%Valuation: $2.82 billionCAGR (2025-2033): 10.1%Demographics: Ages 18-70, expanding treatment-seeking behavior, improved awarenessPreference: Telehealth adoption increasing from 34% in 2025 to projected 52% by 2033 Market Share 2025: 32.8%Valuation: $1.38 billionCAGR (2025-2033): 9.2%Practitioners: Physicians, urologists, sex therapists, psychiatrists, nursing specialistsGrowth: Expanding training programs, clinical research, integrated care models Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms UsedChapter 3 Research MethodologyChapter 4 Premature Ejaculation Treatment Market Overview4.1 Introduction4.1.1 Market Taxonomy4.1.2 Market Definition4.1.3 Macro-Economic Factors Impacting the Market Growth4.2 Premature Ejaculation Treatment Market Dynamics4.2.1 Market Drivers4.2.2 Market Restraints4.2.3 Market Opportunity4.3 Premature Ejaculation Treatment Market - Supply Chain Analysis4.3.1 List of Key Suppliers4.3.2 List of Key Distributors4.3.3 List of Key Consumers4.4 Key Forces Shaping the Premature Ejaculation Treatment Market4.4.1 Bargaining Power of Suppliers4.4.2 Bargaining Power of Buyers4.4.3 Threat of Substitution4.4.4 Threat of New Entrants4.4.5 Competitive Rivalry4.5 Global Premature Ejaculation Treatment Market Size & Forecast, 2025-20344.5.1 Premature Ejaculation Treatment Market Size and Y-o-Y Growth4.5.2 Premature Ejaculation Treatment Market Absolute $ OpportunityChapter 5 Global Premature Ejaculation Treatment Market Analysis and Forecast By Treatment Type5.1 Introduction5.1.1 Key Market Trends & Growth Opportunities By Treatment Type5.1.2 Basis Point Share (BPS) Analysis By Treatment Type5.1.3 Absolute $ Opportunity Assessment By Treatment Type5.2 Premature Ejaculation Treatment Market Size Forecast By Treatment Type5.2.1 Pharmaceutical5.2.2 Behavioral Therapy5.2.3 Devices5.3 Market Attractiveness Analysis By Treatment TypeChapter 6 Global Premature Ejaculation Treatment Market Analysis and Forecast By Distribution Channel6.1 Introduction6.1.1 Key Market Trends & Growth Opportunities By Distribution Channel6.1.2 Basis Point Share (BPS) Analysis By Distribution Channel6.1.3 Absolute $ Opportunity Assessment By Distribution Channel6.2 Premature Ejaculation Treatment Market Size Forecast By Distribution Channel6.2.1 Hospitals6.2.2 Clinics6.2.3 Online Pharmacies6.2.4 Retail Pharmacies6.3 Market Attractiveness Analysis By Distribution ChannelChapter 7 Global Premature Ejaculation Treatment Market Analysis and Forecast By End-User7.1 Introduction7.1.1 Key Market Trends & Growth Opportunities By End-User7.1.2 Basis Point Share (BPS) Analysis By End-User7.1.3 Absolute $ Opportunity Assessment By End-User7.2 Premature Ejaculation Treatment Market Size Forecast By End-User7.2.1 Men7.2.2 Healthcare Providers7.3 Market Attractiveness Analysis By End-UserChapter 8 Global Premature Ejaculation Treatment Market Ana Device manufacturers including Stud 100 parent company maintained market presence with $78 million in annual PE-related device revenues, while emerging device companies remained largely pre-commercial or early-stage revenue generation.

Uses of Tadalafil and Dapoxetine

The competitive landscape for premature ejaculation treatment is characterized by fragmented markets with distinct competitive dynamics across pharmaceutical, behavioral, and device segments. The pharmaceutical segment remains dominated by major multinational pharmaceutical corporations benefiting from established manufacturing capabilities, regulatory relationships, and distribution networks. Takeda Pharmaceutical maintains market leadership through dapoxetine formulations, generating $127 million in revenues during 2025 through controlled direct marketing and partnerships with telehealth platforms. Pfizer Inc., leveraging its extensive urology portfolio including sildenafil and tadalafil, has integrated dapoxetine licensing into comprehensive sexual dysfunction platforms, capturing 18% of the pharmaceutical PE treatment market segment. Eli Lilly and Company has expanded sexual dysfunction treatment capabilities through tadalafil-based approaches and emerging novel compounds, positioning for competitive growth through the forecast period.

Phosphodiesterase 5 inhibitors

Bayer AG, GlaxoSmithKline, and Merck & Co. maintain presence through SSRI formulations and licensed generic agreements, collectively controlling approximately 24% of the pharmaceutical PE treatment market. Generic manufacturers including Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Viatris have expanded market presence through low-cost dapoxetine and SSRI generic formulations, capturing 34% market share and substantially compressing branded manufacturer pricing power. Emerging pharmaceutical competitors from India and China, including companies like Cadila Healthcare and China Biologic Products, have entered PE treatment markets through generic offerings and novel formulations, intensifying competitive pressure. Competition within behavioral therapy markets remains fragmented among independent sex therapists, psychological practices, and emerging digital therapy platforms. Branded dapoxetine commanded premium pricing of $1.80 to $2.40 USD per dose through 2025, while generic equivalents were priced at $0.48 to $0.72 USD, representing 70% to 78% cost reduction and driving generic market capture from 28% in 2020 to 54% by 2025.

Who Is Dapoxetine (Priligy) Suitable For?

Clinical outcome registries and real-world evidence databases could validate novel treatment protocols, supporting regulatory approvals and insurance coverage expansion. Biosimilar development for biologically-derived PE therapeutics represents emerging opportunity as multiple biologics enter development pipelines. Integration of behavioral health platforms with pharmaceutical management through digital therapeutics could expand therapeutic efficacy and improve patient outcomes across treatment modalities. Key market threats include pricing pressure from generic dapoxetine formulations and off-label SSRI prescriptions, with generic market share expanding from 28% in 2020 to 54% by 2025, compressing pharmaceutical manufacturer margins from 68% to 72% historically to 34% to 42% currently. Regulatory restrictions on online pharmacy operations in certain markets including the European Union could disrupt the fastest-growing distribution channel, potentially reducing overall market growth by 1.8% to 2.4%.

Study Locations

Treatment failure rates of 18% to 24% among certain PE phenotypes, particularly comorbid cases, limit market expansion potential and create patient frustration driving abandonment of treatment-seeking. Psychological and lifestyle counseling alone demonstrate comparable efficacy to pharmaceutical interventions in certain patient subsets, creating competition from lower-cost behavioral alternatives; behavioral therapy reimbursement expansion could cannibalize pharmaceutical segment revenues by 12% to 18% through 2033. Data privacy concerns regarding digital health platforms handling sensitive sexual health information could limit telehealth market expansion in privacy-conscious jurisdictions including Europe and parts of Asia. Stigma persistence in traditionally conservative cultures continues limiting treatment-seeking, with PE treatment adoption remaining below 5% of affected populations in certain Middle Eastern and East Asian markets despite clinical need. COVID-19 pandemic normalization and return to in-person healthcare could reduce telehealth utilization from 34% back to estimated 18% to 22%, limiting digital-driven market expansion. Branded formulations maintain competitive positioning through superior marketing, established physician relationships, and patient preference driven by perceived superior quality, though clinical efficacy remains equivalent between branded and generic dapoxetine formulations across randomized trials. Market Share 2025: 58.4%Valuation: $2.45 billionCAGR (2025-2033): 9.1%Includes: Dapoxetine, SSRIs, topical anesthetics, combination therapiesKey Driver: FDA approvals, insurance coverage expansion, telehealth accessibility Market Share 2025: 23.8%Valuation: $998 millionCAGR (2025-2033): 10.4%Includes: Cognitive-behavioral therapy, sex therapy, couples counseling, start-stop techniqueKey Driver: Patient preference, improved therapist training, insurance coverage expansion Market Share 2025: 17.8%Valuation: $746 millionCAGR (2025-2033): 11.4%Includes: Topical anesthetic devices, mechanical solutions, vibration therapy, wearablesKey Driver: Innovation, non-systemic safety profiles, technological advancement Market Share 2025: 29.4%Valuation: $1.23 billionCAGR (2025-2033): 8.2%Services: Specialty sexual medicine departments, multidisciplinary teams, complex case managementOpportunity: Telemedicine expansion, integrated care coordination Market Share 2025: 34.2%Valuation: $1.44 billionCAGR (2025-2033): 10.6%Services: Specialized sexual medicine, urology practices, dermatology integrationOpportunity: Network expansion, emerging market penetration Market Share 2025: 19.8%Valuation: $832 millionCAGR (2025-2033): 15.2%Services: Digital consultations, direct fulfillment, subscription models, convenience accessOpportunity: Regulatory expansion, payment innovation Market Share 2025: 16.6%Valuation: $696 millionCAGR (2025-2033): 4.1%Services: Traditional brick-and-mortar operations, counseling, in-person consultationsOpportunity: Hybrid clinic models, underserved populations Market Share 2025: 67.2%Valuation: $2.82 billionCAGR (2025-2033): 10.1%Demographics: Ages 18-70, expanding treatment-seeking behavior, improved awarenessPreference: Telehealth adoption increasing from 34% in 2025 to projected 52% by 2033 Market Share 2025: 32.8%Valuation: $1.38 billionCAGR (2025-2033): 9.2%Practitioners: Physicians, urologists, sex therapists, psychiatrists, nursing specialistsGrowth: Expanding training programs, clinical research, integrated care models Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms UsedChapter 3 Research MethodologyChapter 4 Premature Ejaculation Treatment Market Overview4.1 Introduction4.1.1 Market Taxonomy4.1.2 Market Definition4.1.3 Macro-Economic Factors Impacting the Market Growth4.2 Premature Ejaculation Treatment Market Dynamics4.2.1 Market Drivers4.2.2 Market Restraints4.2.3 Market Opportunity4.3 Premature Ejaculation Treatment Market - Supply Chain Analysis4.3.1 List of Key Suppliers4.3.2 List of Key Distributors4.3.3 List of Key Consumers4.4 Key Forces Shaping the Premature Ejaculation Treatment Market4.4.1 Bargaining Power of Suppliers4.4.2 Bargaining Power of Buyers4.4.3 Threat of Substitution4.4.4 Threat of New Entrants4.4.5 Competitive Rivalry4.5 Global Premature Ejaculation Treatment Market Size & Forecast, 2025-20344.5.1 Premature Ejaculation Treatment Market Size and Y-o-Y Growth4.5.2 Premature Ejaculation Treatment Market Absolute $ OpportunityChapter 5 Global Premature Ejaculation Treatment Market Analysis and Forecast By Treatment Type5.1 Introduction5.1.1 Key Market Trends & Growth Opportunities By Treatment Type5.1.2 Basis Point Share (BPS) Analysis By Treatment Type5.1.3 Absolute $ Opportunity Assessment By Treatment Type5.2 Premature Ejaculation Treatment Market Size Forecast By Treatment Type5.2.1 Pharmaceutical5.2.2 Behavioral Therapy5.2.3 Devices5.3 Market Attractiveness Analysis By Treatment TypeChapter 6 Global Premature Ejaculation Treatment Market Analysis and Forecast By Distribution Channel6.1 Introduction6.1.1 Key Market Trends & Growth Opportunities By Distribution Channel6.1.2 Basis Point Share (BPS) Analysis By Distribution Channel6.1.3 Absolute $ Opportunity Assessment By Distribution Channel6.2 Premature Ejaculation Treatment Market Size Forecast By Distribution Channel6.2.1 Hospitals6.2.2 Clinics6.2.3 Online Pharmacies6.2.4 Retail Pharmacies6.3 Market Attractiveness Analysis By Distribution ChannelChapter 7 Global Premature Ejaculation Treatment Market Analysis and Forecast By End-User7.1 Introduction7.1.1 Key Market Trends & Growth Opportunities By End-User7.1.2 Basis Point Share (BPS) Analysis By End-User7.1.3 Absolute $ Opportunity Assessment By End-User7.2 Premature Ejaculation Treatment Market Size Forecast By End-User7.2.1 Men7.2.2 Healthcare Providers7.3 Market Attractiveness Analysis By End-UserChapter 8 Global Premature Ejaculation Treatment Market Ana